Frankfurt
13.10.26 | 15:25
4,320 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | PolyPid Ltd.: European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX100 | 5 | GlobeNewswire (USA) | ||
| 01.10. | PolyPid Ltd. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 01.10. | PolyPid Ltd.: PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization Opportunities | 226 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by... ► Artikel lesen | |
| 12.08. | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 9 | SEC Filings | ||
| 12.08. | PolyPid GAAP EPS of -$0.35 beats by $0.03 | 5 | Seeking Alpha | ||
| 12.08. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 1.284 | GlobeNewswire (Europe) | FDA Accepted D-PLEX100 NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization... ► Artikel lesen | |
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 12.08. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | 7 | GlobeNewswire (USA) | ||
| 29.07. | PolyPid rises as lead product granted FDA priority review | 2 | Seeking Alpha | ||
| 29.07. | PolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up | 1 | RTTNews | ||
| 29.07. | PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | 721 | GlobeNewswire (Europe) | PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million... ► Artikel lesen | |
| 29.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | H.C. Wainwright reiterates Buy on PolyPid stock, $13 target | 3 | Investing.com | ||
| 21.07. | PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada | 6 | Contract Pharma | ||
| 21.07. | PolyPid Partners With Azurity In D-PLEX100 Commercialization Deal Worth Over $320 Million | 1 | pulse2.com | ||
| 21.07. | PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada | 4 | Investing.com | ||
| 21.07. | PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | 529 | GlobeNewswire (Europe) | PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to... ► Artikel lesen | |
| 15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | PolyPid Ltd.: PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 | 249 | GlobeNewswire (Europe) | If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,25 | +1,07 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Auf dem jährlichen Esmo-Krebskongress ab dem 23. Oktober in Madrid erwarte... ► Artikel lesen | |
| EVOTEC | 2,608 | +6,71 % | BioTech-Rally 2027: Patente, Blockbuster und Biosimilars! Im Fokus stehen Bayer, Formycon, Evotec und Novo Nordisk | Der Sturm im Pharma-Sektor nimmt weiter Fahrt auf! Auslaufende Patente und laborierende Gesundheits-Systeme bringen alte Margen-Blockbuster ins Wanken, denn gesellschaftliche Veränderungen und die Sparzwänge... ► Artikel lesen | |
| VALNEVA | 2,513 | -1,10 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| AMGEN | 382,10 | +3,62 % | Amgen springt nach Kursziel-News - was jetzt zählt | ||
| PALATIN TECHNOLOGIES | 7,750 | -6,17 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,716 | -10,05 % | Ocugen lizenziert Gentherapie OCU400 für MENA-Region an Roots Pharma | ||
| VIKING THERAPEUTICS | 23,350 | -2,10 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity | SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,221 | -9,05 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,025 | +0,49 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,381 | +0,79 % | NurExone: Vom Rückenmarks-Trauma bis zur Sehnerv-Regeneration | ||
| ABIVAX | 79,40 | +2,92 % | Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization | ||
| SAREPTA THERAPEUTICS | 14,820 | +0,54 % | Sarepta shares preclinical data on DM1 treatment candidate | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,803 | -1,80 % | PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics | ||
| IBIO | 0,748 | +7,02 % | iBio, Inc. - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 51,92 | -0,04 % | Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.